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DEN-induced Ras membrane activity and induces apoptosis
in transformed hepatocytes as indicated by high liver
caspase 3 activity and an increased number of Tunel positive
cells in GSTp-expressing hepatocytes. Apoptosis induction is
associated with up-regulation of Fas, Fas ligand and JNK
phosphosphorylation that occurs independently of TNFa and
Trail. Bax, Bcl2, Bcl-xl expression and cytochrome C release
is not affected by FTS.
Conclusions: FTS inhibits Ras activation in the liver
and prevents preneoplastic liver nodule development by
inducing apoptosis in transformed hepatocytes. FTS-induced
apoptosis is related to activation of the extrinsic pathway
involving the Fas/Fas ligand system. Therefore, FTS might
be a promising agent for the development of new
therapeutic strategies in HCC.
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Hepatocellular carcinoma (HCC), also known as primary
liver cancer, is the ﬁfth most common cancer worldwide. No
completely accurate screening test for liver cancer exists.
Doctors sometimes use a blood test that checks for the
presence of alpha-fetoprotein (AFP) a type of protein not
normally found in adults to screen people at high risk of
the disease.
Unfortunately, an elevated level of AFP is detectable in
only about two-thirds of patients with early-stage HCC,
and high mortality from HCC is due to the inability to
detect these cancers in their earliest stages. Thus, to detect
small tumors, a very sensitive biomarker is needed, with
an intensity that should be proportional to the size of the
tumor.
Protein glycosylation, the most common form of co-
translational modiﬁcation of proteins, is the enzymatic
addition of sugars or oligosaccharides (or glycans) to
proteins. Protein glycosylation increases the diversity of
the functions of proteins encoded in the genome. The result
is that different glycomes of the same protein may have
different functional, kinetic or physical properties. Because
the condition of the cells largely regulates glycosylation
pathway, the type of glycan produced by cells, tissue, or
organism could reﬂect their current physiological state.
This means that the sugar chains can be altered by the
physiological or pathophysiological condition of the cell.
Our group took advantage of a recently developed technique
to study the total glycome (N-linked sugars) pattern of
protein mixtures, e.g. serum proteins. Sugar trees are cut
from the proteins, collected and separated. We have been
able to analyze the serum samples of over 500 cirrhosis
patients. It was clear that the changes in serum glycome
correlated with the presence of tumors and with tumor
size. This study included 450 HBV-infected patients with
liver ﬁbrosis, cirrhosis and HCC. We found that a branch
alpha(1,3)-fucosylated triantennary glycan (NA3Fb) was
more abundant in HCC patients than in cirrhosis patients,
ﬁbrosis patients and healthy blood donors, whereas a
bisecting core alpha (1,6)-fucosylated biantennary glycan
(NA2FB) was elevated in cirrhosis patients. The ratio of
these values forms the basis of the new blood test (the
log ratio of peak9/peak7, renamed as GlycoHCCTest). Using
GlycoHCCTest, we were able to make the correct diagnosis
in 70% of the cases, a success rate that equals that of the
AFP tumor marker currently used in the clinic. Promisingly,
when the AFP test was used in combination with the new
GlycoHCCTest, the accuracy of HCC diagnosis increased
dramatically. The new glycomic test succeeded in detecting
the liver cancer in more than half of the patients with
cirrhosis and cancer of the liver for whom the AFP test was
inconclusive.
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Aims: To identify the HBV oncogenic mutations associated
to the Chinese patients with HCC.
Method: For mutation screening, HBV preS/S gene, X gene
and precore region were ampliﬁed from liver tumor and
their matched paratumor tissue by PCR and analyzed by
direct sequencing. Cassette ligation mediated PCR was used
to analyze HBx integration mutation.
Results: HBV mutation was analyzed in 41 tumor tissues
and 33 non-tumor tissues (among them 32 were paired).
Phylogenetic analysis revealed that 87.3% strains were
genotype C, 8% genotype B, 1.6% genotype D, 3.1%
genotype A. From these samples, pre-S/S gene and X gene
and precore regions from 110 sequences were analyzed
separately. X gene’s carboxyl-terminal deletion (from 6 to
114 amino acids) was found in 20/38 (52.6%) of tumor
samples and only in 9/30 (30%) of paratumor samples.
Concordant to our previous work, pre-S1 start codon in-
frame deletion, pre-S2 start codon mutation and pre-S2
in-frame deletion were all detected in both tumor tissue
and paratumor tissues tested, with a higher tendency
in tumor samples. Interestingly, pre-S1 deletion involving
the S promoter was found in 5 tumor tissue while none
in the paired paratumor tissues, indicating the tumor
associated mutation. However, it is noteworthy that a
higher T1762/A1764 mutation and precore A1896 mutation
frequencies were found in our study: T1762/A1764 mutation
or deletion in 31/41 (75.6%) of tumor samples and in
26/30 (86.7%) paratumor samples; the A1896 mutation
or deletion in 24/37 (64.9%) tumor samples and in
19/28(67.9%) paratumor sample, though there was no
signiﬁcant difference. HBx integration was detected in 7/32
HCC samples and only in 1/22 paratumor samples (among
them 19 were paired). In 2 tumor samples, 2 different
HBx integration sites were found. Ten of 11 integration
events resulted in HBx C-terminal truncated mutations,
except 1 interstitial deletion within the HBx gene in a
tumor sample. Interestingly, though the integration sites in
human genome was random, 5 of 11 breaking sites (4 in the
tumor and 1 in the paratumor sample) were within the DR1
sequence.
Conclusion: Pre-S1 deletion involved S promoter sequence
was only demonstrated in tumor tissues and indicated such
mutation was probably oncogenic; HBx carboxyl-terminal
deletion were more common in tumor than in paratumor
tissues tested, implicating a role in liver carcinogenesis.
In contrast to several previous reports, high frequency
mutations involving pre-S2 gene, X gene, BCP, T1762/A1764
and pre-C A1896 were found in both tumor and paratumor
tissues with no signiﬁcant difference. It is suggested that
such mutations were simply as a result of accumulation with
time of persistent infection and not oncogenic.
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The European Liver Transplantation registree (ELTR) has
cumulated data concerning 54,133 cadaveric full-size
